Pei-Wen Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Pei-Wen Lee has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Bo-Sheng Wu
Department of Medical Education, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 83301, Taiwan
1 shared publication - Chih-Yu Yang
Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
1 shared publication - Oscar Kuang-Sheng Lee
Department of Biotechnology Medicine, MacKay Memorial Hospital, Taipei, Taiwan
1 shared publication
Latest Publications
- Open Access
- 22 October 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (21) , 11406
Molecular Mechanisms of Mesenchymal Stem Cell-Based Therapy in Acute Kidney Injury
Acute kidney injury (AKI) causes a lot of harm to human health but is treated by only supportive therapy in most cases. Recent evidence shows that mesenchymal stem cells (MSCs) benefit kidney regeneration through releasing paracrine factors and extracellular vesicles (EVs) to the recipient kidney cells and are considered to be promising cellular therapy for AKI. To develop more efficient, precise therapies for AKI, we review the therapeutic mechanism of MSCs and MSC-derived EVs in AKI and look for a better understanding of molecular signaling and cellular communication between donor MSCs and recipient kidney cells. We also review recent clinical trials of MSC-EVs in AKI. This review summarizes the molecular mechanisms of MSCs’ therapeutic effects on kidney regeneration, expecting to comprehensively facilitate future clinical application for treating AKI.
- 22 October 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (21) , 11406
Open AccessMolecular Mechanisms of Mesenchymal Stem Cell-Based Therapy in Acute Kidney Injury
Acute kidney injury (AKI) causes a lot of harm to human health but is treated by only supportive therapy in most cases. Recent evidence shows that mesenchymal stem cells (MSCs) benefit kidney regeneration through releasing paracrine factors and extracellular vesicles (EVs) to the recipient kidney cells and are considered to be promising cellular therapy for AKI. To develop more efficient, precise therapies for AKI, we review the therapeutic mechanism of MSCs and MSC-derived EVs in AKI and look for a better understanding of molecular signaling and cellular communication between donor MSCs and recipient kidney cells. We also review recent clinical trials of MSC-EVs in AKI. This review summarizes the molecular mechanisms of MSCs’ therapeutic effects on kidney regeneration, expecting to comprehensively facilitate future clinical application for treating AKI.